SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin gets EIR from USFDA for API manufacturing facility in Visakhapatnam

19 Jun 2023 Evaluate

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its API manufacturing facility located in Visakhapatnam (Vizag), India. The EIR was issued post the last inspection of the facility conducted from March 6, 2023 to March 10, 2023. The inspection closed with the facility receiving an inspection classification of ‘No Action Indicated’ (NAI).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2361.25 57.55 (2.50%)
04-May-2026 11:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1823.85
Dr. Reddys Lab 1305.70
Cipla 1328.85
Zydus Lifesciences 901.60
Lupin 2361.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×